icon
icon
icon
icon
Upgrade
icon

Zymeworks (ZYME) 1 Aug 24 2024 Q2 Earnings call transcript

AInvestFriday, Aug 2, 2024 11:03 pm ET
1min read

Zymeworks reported a net loss of $69.3 million for the second quarter of 2024, a decrease from the $75.5 million net loss in the same period last year. The decrease in net loss was primarily due to lower research and development and general and administrative expenses. Revenue for the second quarter of 2024 was $29.3 million, down from $42.6 million in the same period in 2023. This decrease was due to a decrease in revenue from Jazz for development support and drug supply, partially offset by a milestone payment of $8 million from BeiGene in relation to the acceptance of the BLA for zanidatamab in China. Overall operating expenses for the second quarter of 2024 were $110 million, a decrease of 11% year-over-year, due to a decrease in both research and development and general and administrative expenses. The company recorded a non-cash impairment charge of $17.3 million due to the discontinuation of the Zanidatamab zovodotin clinical development program.

Pipeline and Clinical Programs

Zymeworks made significant progress in the development of its pipeline, including the global regulatory review of its late-stage asset, zanidatamab, for second-line treatment of biliary tract cancers. The company received priority review of the Biologics License Application for zanidatamab in the United States, with a target action date of November 29, 2024. Jazz is also conducting a pivotal Horizon GEA-01 trial evaluating zanidatamab in first-line gastroesophageal adenocarcinoma, with top-line progression-free survival data expected in the second quarter of 2021. Zymeworks also transitioned two early-stage programs into clinical candidates, with IND applications cleared by the FDA for ZW191 and ZW171, and first-in-human studies planned to initiate in the second half of 2024. The company also made the decision to formally discontinue the clinical development program for its HER2-targeted antibody drug conjugate, zanidatamab zovadotin.

Looking Ahead

Zymeworks is focused on advancing its clinical pipeline, including the initiation of two Phase 1 trials in 2024 for non-small cell lung cancer, and the transition of two early-stage programs into clinical candidates. The company remains committed to its strategy of refocusing the business and building a diverse clinical stage product pipeline of Antibody Drug Conjugates and multi-specific antibody therapeutics. With a strong financial position and a clear focus on innovative treatments, Zymeworks is well-positioned to drive growth and deliver value for its shareholders.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.